Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836

Osivax  Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 Grant to support preclinical evaluation of OVX836 in providing protection against pandemic influenza strains  OVX836 has already been evaluated in several Phase 2 clinical trials against seasonal influenza with initial signals of broad-spectrum protection Lyon, France – December 5, 2023 …

Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836

Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836 OVX836 demonstrated positive safety and immunogenicity data across three dose levels A notable signal of protection of 84% was observed against symptomatic influenza infection Lyon, France – July 28, 2023 – Osivax, a a biopharmaceutical company developing vaccines to provide …

Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs

Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs  Australia-based Phase 2a clinical study to evaluate broad-spectrum influenza vaccine candidate, OVX836 in combination with Quadrivalent Influenza Vaccines (QIVs) An enrollment of over 500 participants across Australia is anticipated  Lyon, France – June 15, 2023 – Osivax, a biopharmaceutical company developing …

Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine

Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine A Bill & Melinda Gates Foundation grant will be used to expand research and development of OVX836 in a wide range of seasonal and highly pathogenic influenza strains  Osivax continues evaluating OVX836 across several phase 2 clinical trials in healthy volunteers …